Exercise ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症10

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05239611
(ClinicalTrials.gov)
February 14, 202210/1/2022Feasibility of Home-based Exercise Program for Adults With Cystic FibrosisFeasibility of Home-based Exercise Program for Adults With Cystic Fibrosis to Improve Patient-centered Outcomes, Including a Novel Measure of VentilationCystic FibrosisDrug: ExerciseUniversity of Kansas Medical CenterNULLRecruiting18 YearsN/AAll30Phase 2United States
2NCT04039087
(ClinicalTrials.gov)
September 5, 201928/7/2019Sildenafil Exercise: Role of PDE5 InhibitionMechanisms of Exercise Intolerance in Cystic Fibrosis: Role of PDE5 InhibitionCystic FibrosisDrug: Sildenafil 40mg oral capsule;Drug: Placebo Oral capsuleNational Jewish HealthAugusta University;Cystic Fibrosis FoundationRecruiting9 YearsN/AAll40Phase 2/Phase 3United States
3NCT03522831
(ClinicalTrials.gov)
May 1, 201819/3/2018CF BronchodilationA Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic FibrosisLung Diseases;Cystic FibrosisDrug: Salbutamol;Drug: PlaceboUniversity of British ColumbiaNULLActive, not recruiting19 YearsN/AAll20N/ACanada
4NCT02875366
(ClinicalTrials.gov)
September 201615/8/2016A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationA Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCystic FibrosisDrug: LUM/IVA;Drug: PlaceboVertex Pharmaceuticals IncorporatedNULLCompleted12 YearsN/AAll70Phase 4Australia;United Kingdom
5EUCTR2016-000066-34-GB
(EUCTR)
24/06/201625/07/2017A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationA Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation. Cystic fibrosis in patients homozygous for the F508del-CFTR Mutation
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Orkambi
Product Name: lumacaftor/ivacaftor
Product Code: VX-809/VX-770
INN or Proposed INN: lumacaftor
Other descriptive name: LUMACAFTOR
INN or Proposed INN: IVACAFTOR
Vertex Pharmaceuticals IncorporatedNULLNot Recruiting Female: yes
Male: yes
66 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesAustralia;United Kingdom
6NCT02057458
(ClinicalTrials.gov)
April 20144/2/2014Blood Flow and Vascular Function in Cystic FibrosisRole of Blood Flow and Vascular Function on Exercise Capacity in Cystic FibrosisCystic FibrosisDrug: Sildenafil (Acute-1 hour);Drug: Sildenafil (Subchronic-4 weeks);Drug: PlaceboAugusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 YearsN/AAll19Phase 2United States
7NCT01937325
(ClinicalTrials.gov)
February 20144/9/2013CPET in CF Patients With One G551D Mutation Taking VX770Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX770 (Ivacaftor)Cystic FibrosisDrug: ivacaftor;Drug: placeboThe AlfredNULLActive, not recruiting16 Years70 YearsBoth20Phase 4Australia
8NCT01772758
(ClinicalTrials.gov)
August 201116/10/2012Cystic Fibrosis and Endothelial Function: At Rest and During ExerciseInfluence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During ExerciseCystic FibrosisDrug: BH4 5mg;Drug: BH4 20mg;Dietary Supplement: Antioxidant CocktailAugusta UniversityNULLCompleted7 YearsN/AAll64Phase 2United States
9NCT00434278
(ClinicalTrials.gov)
March 200711/2/2007A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung DiseaseCystic FibrosisDrug: Dornase alfa;Drug: placeboGenentech, Inc.NULLTerminated14 YearsN/AAll27Phase 4United States
10NCT00164021
(ClinicalTrials.gov)
February 200113/9/2005The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung TransplantationThe Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal FunctionCystic FibrosisProcedure: Physiotherapy, exercise, percutaneous gastrostomy feeds;Drug: Anti-reflux pharmacotherapyBayside HealthThe Alfred;Monash UniversityRecruiting16 Years70 YearsBoth180N/AAustralia